PT804584E - Sequencias de virus da hepatite c genotipo 7 e sua utilizacao como agentes profilacticos terapeuticos e de diagnostico - Google Patents

Sequencias de virus da hepatite c genotipo 7 e sua utilizacao como agentes profilacticos terapeuticos e de diagnostico

Info

Publication number
PT804584E
PT804584E PT95936537T PT95936537T PT804584E PT 804584 E PT804584 E PT 804584E PT 95936537 T PT95936537 T PT 95936537T PT 95936537 T PT95936537 T PT 95936537T PT 804584 E PT804584 E PT 804584E
Authority
PT
Portugal
Prior art keywords
sequences
therapeutic
genotype
hepatitis
proprietary
Prior art date
Application number
PT95936537T
Other languages
English (en)
Inventor
Geert Maertens
Lieven Stuyver
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26137782&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT804584(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Publication of PT804584E publication Critical patent/PT804584E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT95936537T 1994-10-21 1995-10-23 Sequencias de virus da hepatite c genotipo 7 e sua utilizacao como agentes profilacticos terapeuticos e de diagnostico PT804584E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94870166 1994-10-21
EP95870076 1995-06-28

Publications (1)

Publication Number Publication Date
PT804584E true PT804584E (pt) 2002-11-29

Family

ID=26137782

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95936537T PT804584E (pt) 1994-10-21 1995-10-23 Sequencias de virus da hepatite c genotipo 7 e sua utilizacao como agentes profilacticos terapeuticos e de diagnostico

Country Status (12)

Country Link
US (2) US7129337B1 (pt)
EP (2) EP0804584B2 (pt)
JP (2) JPH10507643A (pt)
AT (1) ATE218617T1 (pt)
AU (1) AU702436B2 (pt)
BR (1) BR9509421A (pt)
CA (1) CA2201703A1 (pt)
DE (1) DE69526973T3 (pt)
DK (1) DK0804584T3 (pt)
ES (1) ES2176342T5 (pt)
PT (1) PT804584E (pt)
WO (1) WO1996013590A2 (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9620075D0 (en) * 1996-09-26 1996-11-13 Dynal As Method
US7078500B1 (en) * 1998-01-30 2006-07-18 The General Hospital Corporation Genetic immunization with nonstructural proteins of hepatitis C virus
BRPI9909678B8 (pt) 1998-04-17 2021-05-25 Fujirebio Europe N V aperfeiçoados ensaios de imunodiagnóstico usando agentes redutores
DE19980730D2 (de) * 1998-04-28 2001-05-10 Wolfgang Bergter Radioimmunpharmaka zur Therapie der Hepatitis C
PT1090033E (pt) * 1998-06-24 2005-05-31 Innogenetics Nv Particulas de proteinas de envelope do hcv: utilizacao para vacinacao
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US6858590B2 (en) 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
WO2002014362A2 (en) * 2000-08-17 2002-02-21 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7101561B2 (en) 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
GB0126782D0 (en) * 2001-11-07 2002-01-02 Medical Res Council Assay
US8124747B2 (en) * 2003-08-29 2012-02-28 Innogenetics HCV clade and prototype sequences thereof
CA2552949C (en) 2004-01-07 2012-10-02 Third Wave Technologies, Inc. Determination of hepatitis c virus genotype
RU2267496C2 (ru) * 2004-01-15 2006-01-10 Сергей Иванович Черныш Противоопухолевые и антивирусные пептиды
CA2618429A1 (en) * 2005-05-25 2007-03-22 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
US7919242B2 (en) 2005-06-30 2011-04-05 Roche Molecular Systems, Inc. Light emission modifiers and their uses in nucleic acid detection, amplification and analysis
EP2361638B1 (en) 2005-12-12 2014-01-15 AC Immune S.A. A beta 1-42 specific monoclonal antibodies with therapeutic properties
TWI551607B (zh) 2006-07-14 2016-10-01 Ａｃ免疫公司 人類化抗體
SI2468770T1 (en) 2006-07-14 2018-05-31 Ac Immune S.A. A humanized antibody against amyloid beta.
CN101563362B (zh) * 2006-08-25 2015-02-11 麦克法兰布奈特医疗研究与公共健康研究所有限公司 重组hcv e2糖蛋白
EP2463389A1 (en) 2006-10-20 2012-06-13 Innogenetics N.V. Methodology for analysis of sequence variations within the HCV NS5B genomic region
WO2008046923A2 (en) 2006-10-20 2008-04-24 Innogenetics N.V. Methodology for analysis of sequence variations within the hcv ns3/4a genomic region
US20100183513A1 (en) 2006-11-24 2010-07-22 Wolfgang Froestl N-(methyl) -1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's
CN104761641A (zh) 2007-06-12 2015-07-08 Ac免疫有限公司 β淀粉样蛋白的人源化抗体
TWI516500B (zh) 2007-06-12 2016-01-11 Ａｃ免疫公司 抗β類澱粉蛋白單株抗體
US20100227314A1 (en) * 2007-08-09 2010-09-09 Dmitry Alexandrovich Gryadunov Method of identification of genotype and subtype of hepatitis c virus on a biological microchip
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
AU2008311366B2 (en) 2007-10-05 2015-03-12 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
WO2009130588A2 (en) * 2008-04-22 2009-10-29 Tripep Ab Immunogen platform
EP2311823A1 (en) 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
EP2377860A1 (en) 2010-04-16 2011-10-19 AC Immune S.A. Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
MX337548B (es) 2010-04-16 2016-03-10 Ac Immune Sa Nuevos compuestos para tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide.
US8962241B2 (en) * 2010-07-20 2015-02-24 California Institute Of Technology Triggered molecular geometry based bioimaging probes
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
JP6371526B2 (ja) 2010-10-07 2018-08-08 エーシー イミューン エス．エー． タウを認識するリン酸化部位特異的抗体
CA2813833C (en) 2010-10-26 2020-09-22 Ac Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
CA2850686C (en) 2011-10-07 2020-09-08 Ac Immune S.A. Phosphospecific antibodies recognising tau
WO2013151762A1 (en) 2012-04-05 2013-10-10 Ac Immune S.A. Humanized tau antibody
EP2859017B1 (en) 2012-06-08 2019-02-20 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2014004639A1 (en) 2012-06-26 2014-01-03 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
CN102766701B (zh) * 2012-07-04 2016-05-04 福州泰普生物科学有限公司 丙型肝炎病毒基因分型的试剂盒及方法
SG11201501464TA (en) 2012-08-31 2015-03-30 Sutro Biopharma Inc Modified amino acids comprising an azido group
JP6568514B2 (ja) 2013-03-15 2019-08-28 エーシー イミューン エス．エー． 抗タウ抗体及び使用方法
EP2994754B1 (en) * 2013-05-10 2018-07-25 The United States of America, as represented by The Secretary, Department of Health and Human Services Compositions and methods for simultaneous detection of hcv antigen/antibody
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
JP6820743B2 (ja) 2013-09-05 2021-01-27 エイビー２ バイオ ソシエテアノニム 炎症性疾患におけるｉｌ−１８結合タンパク質（ｉｌ−１８ｂｐ）
US9840493B2 (en) 2013-10-11 2017-12-12 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
CA2972689A1 (en) 2015-03-05 2016-09-09 Ab2 Bio Sa Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
WO2017218698A1 (en) 2016-06-15 2017-12-21 Sutro Biopharma, Inc. Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
GB201807367D0 (en) 2018-05-04 2018-06-20 Univ Newcastle Biomarker
WO2021178597A1 (en) 2020-03-03 2021-09-10 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
EP4146174A1 (en) 2020-05-06 2023-03-15 AB2 Bio SA Il-18 binding protein (il-18bp) in respiratory diseases
EP3943097A1 (en) 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
WO2023166206A1 (en) 2022-03-04 2023-09-07 Ab2 Bio Sa Il-18 binding protein (il-18bp) in the treatment of vexas
WO2024006563A1 (en) 2022-07-01 2024-01-04 Sutro Biopharma, Inc. Il-12 mutants with reduced toxicity, compositions thereof and methods of using the same
WO2024044780A1 (en) 2022-08-26 2024-02-29 Sutro Biopharma, Inc. Interleukin-18 variants and uses thereof
WO2024098023A2 (en) 2022-11-04 2024-05-10 Sutro Biopharma, Inc. Interferon alpha polypeptides and conjugates

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT54896A (en) 1989-03-17 1991-04-29 Chiron Corp Process for producing aquous diagnosticum and vaccine of nanbv
US5372928A (en) 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
CA2065287C (en) 1989-09-15 1999-12-21 Tatsuo Miyamura New hcv isolates
SE9004010D0 (sv) 1989-12-18 1990-12-17 Wellcome Found Viralt medel
CA2045326A1 (en) 1990-06-25 1991-12-26 Hiroto Okayama Non-a, non-b, hepatitis virus particles
KR100193801B1 (ko) 1991-05-08 1999-06-15 케네스 엠. 골드만 진단 및 치료용 c형 간염 바이러스(hcv) 게놈서열
DE69232871T2 (de) * 1991-06-24 2003-05-08 Chiron Corp Polypeptide des hepatitis c-virus (hiv)
EP0532167A3 (en) 1991-08-09 1993-03-31 Immuno Japan Inc. Non-a, non-b hepatitis virus genome, polynucleotides, polypeptides, antigen, antibody and detection systems
CA2116764C (en) 1991-09-13 1999-12-07 Amy J. Weiner Immunoreactive hepatitis c virus polypeptide compositions
DE610436T1 (de) 1991-11-21 1995-08-03 Common Services Agency Detektion des Hepatis-C Virus.
US7157226B1 (en) * 1993-04-27 2007-01-02 Innogenetics S.A. Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
JPH06319563A (ja) * 1993-05-13 1994-11-22 Imuno Japan:Kk Ｃ型肝炎ウイルス遺伝子、オリゴヌクレオチド、並びにｃ型 肝炎ウイルス遺伝子型判定方法
US5514539A (en) 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines

Also Published As

Publication number Publication date
BR9509421A (pt) 1997-09-30
DE69526973D1 (de) 2002-07-11
WO1996013590A2 (en) 1996-05-09
DK0804584T3 (da) 2002-09-23
WO1996013590A3 (en) 1996-08-15
EP1076092A3 (en) 2001-03-28
EP0804584B1 (en) 2002-06-05
EP0804584A1 (en) 1997-11-05
EP0804584B2 (en) 2008-07-09
ES2176342T5 (es) 2010-02-09
DE69526973T2 (de) 2003-01-02
EP1076092A2 (en) 2001-02-14
ATE218617T1 (de) 2002-06-15
AU702436B2 (en) 1999-02-18
AU3844095A (en) 1996-05-23
JP2005118044A (ja) 2005-05-12
US7129337B1 (en) 2006-10-31
DE69526973T3 (de) 2010-01-07
CA2201703A1 (en) 1996-05-09
US20020183508A1 (en) 2002-12-05
JPH10507643A (ja) 1998-07-28
US6974864B2 (en) 2005-12-13
ES2176342T3 (es) 2002-12-01

Similar Documents

Publication Publication Date Title
PT804584E (pt) Sequencias de virus da hepatite c genotipo 7 e sua utilizacao como agentes profilacticos terapeuticos e de diagnostico
BR9405334A (pt) Novas sequências de genótipos de vírus da hepatite c e seu uso como agentes terapêuticos e diagnóstico
DE69334357D1 (de) Nachweis und Typisierung das Hepatitis C Virus (HCV) mittels 5'UTR und NS5 Nukleinsäuresequenzen
MC2188A1 (fr) Diagnostic du nanbv:polynucleotides permettant de depister le virus de l'hepatite c
NO923821D0 (no) Diagnostiske midler
EP0261224A4 (en) SYNTHETIC HTLV III PEPTIDE COMPOSITIONS AND THEIR USE.
DE69015261D1 (de) Verfahren zum Nachweis des humanen Papillomvirus.
NO20000514L (no) Oligonukleotidprimere for effektiv multipleksdeteksjon av Hepatitt C-virus (HCV) og human immunosviktvirus (HIV) og metoder for anvendelse derav
EP1878797A3 (en) Antigenic peptides for grouping hepatitis c virus, kit comprising the same and methods for its grouping using the same
ES2141094T3 (es) Deteccion directa del arn del virus de la hepatitis c.
ATE109158T1 (de) Rubella-e1 und c peptide.
IT1285158B1 (it) Polipeptidi solubili con l'attivita' di serino-proteasi di ns3 del virus dell'epatite c, e procedimento per la loro preparazione e il
DE60029327D1 (de) Nukleinsaüre- und aminosaürensequenzen von infectious salmon anaemia virus, und deren verwendung als impfstoffe
DE68926245D1 (de) Nachweis der basismembrankomponenten, diagnose von krebs und sonstigen krankheiten
ATE482974T1 (de) Multimere peptide, die auf dem hepatitis c virus hüllprotein basieren, für diagnostische verwendung und für impfzwecke
AU756661C (en) Novel (poly)peptides which represent the epitopes of the human herpes virus type 8
IT1273996B (it) Uso di anticorpi che riconoscono la proteina 90k nella diagnostica clinica e nel monitoraggio dei pazienti affetti da epatite virale
EP0391330A3 (de) Verfahren zur Bestimmung von Antikörpern gegen Erreger von Infektionskrankheiten in Körperflüssigkeiten, Mittel dazu und ihre Verwendung in diesem Verfahren
ATE98379T1 (de) Testverfahren des menschlichen b-lymphotropen virus (hblv).